Taking a medical innovation from the conceptual stage to an approved, clinically and market relevant product takes skill, time and money.
Sarsia's highly experienced team of engineers, technologists, biologists and pharmacologists identify and support, through active ownership, innovative research-based companies working to develop and bring to market products with a high medical need.
Life Science prospects are "born global". With world-class research, investing in the Norwegian Life Science sector is an attractive proposition. Sarsia is Norway’s leading early-stage Life Science investment firm. We combine our technological knowledge and solid understanding of the market, with a vibrant international network.
Examples of investment areas:
Biomedicine and biotech
Medical instrumentation and technology platforms
Diagnostic tools and biotechnological products
Marine biology and technology related to aquaculture
Latest news about Life Sciences
Mon Jan 02 2023
Coegin Pharma raises 25 mSEK
Coegin Pharma AB (COEGIN:Nordic GM) raises 25,3 mSEK through combined rights issue and directed new …